SECsense Logo

Oncolytics Biotech Inc. Files Form 6-K for January 2025: Key Insights & Compliance

$ONCY
Form 6-K
Filed on: 2025-01-15
Source
Oncolytics Biotech Inc. Files Form 6-K for January 2025: Key Insights & Compliance

Here are the key insights extracted from the provided section of the financial report:

  1. Document Type: This is a Form 6-K, which is a report of a foreign private issuer to the SEC.
  2. Filing Date: The report covers the month of January 2025.
  3. Registrant Information:
  • Company Name: Oncolytics Biotech Inc.
  • Commission File Number: 001-38512
  • Address: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
  1. Filing Purpose: The report is submitted pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
  2. Annual Report Filing:
  • The registrant indicates that it files annual reports under Form 20-F.
  • It does not file under Form 40-F.
  1. Signature Section:
  • The report is signed by Kirk Look, who is the Chief Financial Officer of Oncolytics Biotech Inc.
  • The signing date is January 15, 2025.
  1. Exhibits:
  • Exhibit 99.1 is referenced as a "Press Release", indicating that additional information may be available in that document.
  1. Legal Compliance: The report includes notes about the regulations governing the submission of Form 6-K, indicating compliance with the SEC's rules regarding paper submissions and foreign issuer requirements.

This document serves as a standard report indicating compliance and basic company information for Oncolytics Biotech Inc. It is important for investors and analysts monitoring the company's regulatory filings and overall compliance status.